TABLE 1.
Clinical and demographic characteristics of study participants
| Characteristic | All participants (N = 442) | Relapse (n = 110) | Non‐relapse (n = 157) | Relapse versus non‐relapse |
|---|---|---|---|---|
| Mean ± SD or no. (%) | Mean ± SD or no. (%) | Mean ± SD or no. (%) | P value | |
| Age (years) | 42 ± 11.8 | 41.59 ± 12.04 | 42.39 ± 11.58 | NS |
| Male sex | 286 (65) | 67 (60.9) | 112 (71.3) | NS |
| White race | 412 (93) | 100 (90.9) | 147 (93.6) | NS |
| Baseline PHQ‐9 score | 9.4 ± 6.1 | 10.24 ± 6.14 | 8.79 ± 6.04 | * |
| Baseline PACS score | 13.38 ± 8.0 | 15.44 ± 8.47 | 11.91 ± 7.37 | * |
| Baseline GAD‐7 score | 9.0 ± 5.9 | 9.35 ± 5.88 | 8.66 ± 5.80 | NS |
| Depression | 102 (23) | 30 (27.2) | 33 (21.0) | NS |
| Anxiety | 141 (31.9) | 33 (30) | 45 (28.6) | NS |
| OCD | 22 (4.9) | 6 (5.4) | 8 (5.0) | NS |
| Social phobia | 54 (12.2) | 14 (12.7) | 16 (10.1) | NS |
| PTSD | 79 (17.8) | 19 (17.2) | 21 (13.3) | NS |
| Panic disorder | 31 (7) | 10 (9.0) | 13 (8.2) | NS |
Note: Relapse was defined as having a standard drink during 3 months of acamprosate treatment, whereas non‐relapse was defined as the maintenance of abstinence from alcohol during 3 months of acamprosate treatment.
Abbreviations: GAD‐7, General Anxiety Disorder 7; NS, not significant; OCD, obsessive–compulsive disorder; PACS, Penn Alcohol Craving Scale; PHQ‐9, Patient Health Questionnaire 9; PTSD, post‐traumatic stress disorder.
*
P < 0.05.